IPD Analytics reads the clock on drug competition

A patent expiry looks wonderfully definite on a spreadsheet. There is a product, a date, and a future in which somebody else can sell a competing medicine. Then a court ruling arrives. Or a regulatory decision. Or the competing product proves difficult to make. The spreadsheet still has its neat little cell. The commercial question has escaped it.

IPD Analytics occupies that space between a recorded date and a usable decision. Its subject is the drug life cycle: how medicines move through development, protection, competition, and changing economics. A manufacturer wants to know when a rival might arrive. A health plan wants to know when its pharmacy budget might change. An investor wants to understand which assumptions deserve another look.

Those are related questions, but answering one does not automatically answer the others. The interesting thing about IPD is its attempt to keep the legal, clinical, and financial versions of the future in the same conversation.

A lawyer’s problem becomes everyone’s problem

Founder and CEO Howard Krass came from corporate law, intellectual-property licensing, and litigation. In 1993, he founded Intellectual Property Development to acquire and commercialize patent rights. IPD Analytics followed in 2002. That chronology matters: the analytical business grew from a founder whose professional background involved what patents could do in practice.

Today, IPD describes a team that includes former Federal Circuit clerks, patent attorneys, litigators, clinical pharmacists, PhD scientists, and forecasters with manufacturer experience. This is an unusual seating plan. Each profession has a different instinct about what makes a drug commercially vulnerable. Putting their work together is central to the product.

The company’s stated ambition includes bringing “efficiency and transparency” to an opaque pharmaceutical market. Its careers material stresses collaboration, open communication, and continuing education. Those are the company’s own descriptions; the observable business choice is to sell access to expert interpretation alongside access to information.

Three clocks, one commercial decision

Start with protection. Global Patent Search lets subscribers investigate patents, extensions, regulatory exclusivities, and litigation. IPD says it covers more than 500,000 patents across 65 countries. Analysts link patents to drugs, build patent families, and verify patent types and expirations. The point is to establish which protections matter to a particular product.

Next comes the competitive pipeline. Life-Cycle Insights tracks brand, generic, and biosimilar launches, legal proceedings, and regulatory developments. Its published description includes pipeline visibility extending up to ten years. Global Life-Cycle Insights adds country-specific analysis across 13 international markets. A worldwide patent collection and a market-specific forecast are different tools; IPD sells both.

Then comes the money. Market & Financial Insights uses forecasts organized around events that can change a product’s prospects. Subscribers can examine forecast inputs, launch scorecards, and comparable launches with analyst commentary. They can also consult the people developing the forecasts. A new event can change the assumptions before it changes reported sales.

The buyer changes. The question changes.

For a generic manufacturer, the practical issue may be whether a proposed product is worth developing. Portfolio & Formulation Insights brings together patent constraints, likely competitors, sales forecasts, formulation considerations, bioequivalence requirements, and actual or estimated active-ingredient costs. Its downloadable models let teams test commercial scenarios against their own development and manufacturing assumptions.

A payer has another job. Payer & Provider Insights supports formulary, clinical, contracting, and market-access decisions. Access Hub collects details such as limited distribution networks, plan coverage restrictions, clinical criteria, and patient assistance programs. A medicine can be approved and still be awkward to obtain or expensive to cover. These products address the operational details that a launch announcement leaves out.

Budget Impact translates market events into customizable models for organizations including hospitals, health plans, and pharmacy benefit managers. CODESOURxCE handles medical-drug coding and reimbursement, including links between National Drug Codes and billing codes. Here, the life-cycle story reaches the billing unit. A promising forecast is of limited use if the institution cannot translate it into its own costs.

The price behind the price

Rebate Monitor tackles a particularly slippery distinction: what a drug appears to sell for and what the manufacturer ultimately receives. It estimates rebates and supply-chain discounts using inputs including manufacturer sales disclosures and third-party utilization data. IPD describes analyst work that triangulates utilization and identifies discount drivers. These are estimates with methodologies, rather than a view into every private contract.

The external evidence is concrete. In May 2019, IPD announced an agreement under which the Institute for Clinical and Economic Review would use its data and expertise for pharmaceutical horizon scanning. ICER’s published work on paroxysmal nocturnal hemoglobinuria later used an IPD estimate as a placeholder price for danicopan. The label matters: a provisional input remains provisional even inside a detailed economic model.

“efficiency and transparency”IPD Analytics’ stated ambition for the pharmaceutical market

A subscription to revising the answer

The business model is subscription access to proprietary platforms and research, supplemented by alerts, reports, data downloads, podcasts, and consultations. IPD’s careers page says its subscriber base spans more than 45 countries. This is professional information sold across manufacturers, payers, providers, supply-chain organizations, law firms, and institutional investors.

There are established alternatives. Clarivate’s Cortellis products combine drug, patent, market, and supplier intelligence. Evaluate Pharma emphasizes consensus forecasts and commercial analysis. The distinction to investigate when buying IPD is the fit between its legal analysis, pharmacy expertise, forecasting, and direct analyst access and the decisions a team actually makes. Product descriptions alone cannot settle comparative accuracy.

The first assumption to challenge in such a plan is that entry produces an immediate, predictable price response. A launch forecast and a savings forecast answer different questions. Checking the evidence behind each gives a team somewhere specific to focus its next conversation. The lesson a reader can copy is procedural. Separate the date competition becomes legally possible from the date entry becomes plausible, then separate entry from its financial effect. Write down the assumptions connecting those steps. Revisit them when evidence changes. IPD’s customizable forecasts and alerts make that sequence a service.

The approach is useful when an organization has consequential, recurring decisions and people able to act on revised evidence. A market forecast still needs local purchasing costs, contracts, patient mix, and implementation choices. In September 2026, IPD’s public activity included presentations on emerging therapies and specialty pipelines. The work keeps returning to the same demanding question: what happens next, and which decision should change because of it?